Bioventus delays Q1 10-Q filing; prelim revenue ~$119M, Adj. EBITDA ~$17M

Bioventus Inc.

Filing delayed due to complexity in tax structure and noncontrolling equity interest calculation.
Preliminary Q1 revenue ~$119M; Adjusted EBITDA ~$17M; no impact on revenue or EBITDA from the calculation.
Company expects to file Form 10-Q by May 16, 2023, and remain in compliance with all financial covenants.
Earnings call rescheduled to May 16, 2023 at 8:30 a.m. ET.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Bioventus Inc. reported the quarter ended April 1, 2023 results: revenue approximately $119 million.

Period: the quarter ended April 1, 2023
Revenue: approximately $119 million
Result: preliminary results

Exact text from the filing

At this time, the Company expects to report revenue for the quarter ended April 1, 2023, of approximately $119 million and Adjusted EBITDA of approximately $17 million.

View on SEC.gov

Browse all earnings releases →

Bioventus Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-017427

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.